<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3276">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030301</url>
  </required_header>
  <id_info>
    <org_study_id>HSV2-101</org_study_id>
    <nct_id>NCT02030301</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effectiveness of two experimental
      therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose escalation study to evaluate the safety, immunogenicity, and efficacy of 3
      doses of HSV plasmid DNA (pDNA) vaccines formulated with Vaxfectin® in subjects with a
      minimum of 1 year of reported history of genital herpes, and either 2 to 9 recurrences
      within the year prior to screening, or 2 to 9 recurrences per year prior to starting
      suppressive therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to Day 420</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral shedding rate change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genital lesion rate change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSV DNA copy numbers change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital recurrence rate compared with placebo</measure>
    <time_frame>Up to Day 330</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell and/or antibody responses change from baseline</measure>
    <time_frame>Baseline, Days 7, 35, 63, 150, 330</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Genital shedding rate change from baseline over time</measure>
    <time_frame>Baseline, Day 150, Day 330</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Subclinical genital shedding rate change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Genital Herpes Simplex Type 2</condition>
  <arm_group>
    <arm_group_label>VCL-HB01, 0.25-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 0.25-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HB01, 0.5-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 0.5-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HM01, 1-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 1-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-HB01</intervention_name>
    <description>Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®</description>
    <arm_group_label>VCL-HB01, 0.25-mL dose</arm_group_label>
    <arm_group_label>VCL-HB01, 0.5-mL dose</arm_group_label>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-HM01</intervention_name>
    <description>Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®</description>
    <arm_group_label>VCL-HM01, 1-mL dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBS</intervention_name>
    <description>Phosphate-buffered saline</description>
    <arm_group_label>PBS, 0.25-mL dose</arm_group_label>
    <arm_group_label>PBS, 0.5-mL dose</arm_group_label>
    <arm_group_label>PBS, 1-mL dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HSV-2 seropositive

          -  A minimum of 1 year of reported history of genital herpes and either 2 to 9
             recurrences within the year prior to screening or 2 to 9 recurrences per year prior
             to starting suppressive therapy

        Exclusion Criteria:

          -  History of receiving an investigational HSV vaccine

          -  Chronic illness for which a subject's immune system is suspected to be impaired or
             altered, such as cancer, autoimmune conditions, or diabetes

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mammen P. Mammen, Jr., MD,FACP,FIDSA</last_name>
    <role>Study Director</role>
    <affiliation>Vical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine Research Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Christian</last_name>
      <phone>205-934-6774</phone>
      <email>lesliejo@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Van Wagoner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phase 1 Solutions</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Gardner</last_name>
      <phone>305-624-9191</phone>
      <phone_ext>8078</phone_ext>
      <email>kimberlygardner@phase1solutions.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Galitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Diseases Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisha Largent, RN</last_name>
      <phone>317-278-1614</phone>
      <email>elargent@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Fife, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Bernert</last_name>
      <phone>503-226-6678</phone>
      <email>rene@westoverheights.com</email>
    </contact>
    <investigator>
      <last_name>Terri Warren, ANP, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Villanueva</last_name>
      <phone>713-528-8818</phone>
      <phone_ext>1201</phone_ext>
      <email>info@ccstexas.com</email>
    </contact>
    <investigator>
      <last_name>Steve K. Tyring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Division of Infectious Diseases</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Moulton</last_name>
      <phone>801-587-3831</phone>
      <email>bryce.moulton@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>John Kriesel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Hauge</last_name>
      <phone>206-520-4340</phone>
      <email>kahauge@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Anna Wald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Simplex Virus, Type 2</keyword>
  <keyword>Herpes</keyword>
  <keyword>HSV-2</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Genitalis</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
